Hans Petter Eikesdal's picture
Lasse Moe, Dagens Medisin

Hans Petter Eikesdal

  • E-mailHans.Eikesdal@uib.no
  • Phone+47 55 58 67 36
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Hans Petter Eikesdal (HPE) is a consultant medical & radiation oncologist, working in the Dept. of Oncology, Haukeland University Hospital, Bergen, Norway (https://helse-bergen.no/en/avdelinger/kreftbehandling-og-medisinsk-fysik...).

His clinical work is dedicated to patients with breast cancer and malignant melanoma, and he is a member of the executive committee for the Norwegian Breast Cancer Group (https://nbcg.no/about/), setting the national guidelines for treatment of breast cancer in Norway (https://www.helsebiblioteket.no/retningslinjer/brystkreft/forord;jsessio...).

He is a senior researcher in the Bergen Breast Cancer Group, working in the Mohn Cancer Research Laboratory (https://www.uib.no/fg/g18). He is heading a research group studying the molecular characteristics governing resistance to endocrine therapy and chemotherapy in hormone receptor positive breast cancer and chemoresistance in triple negative breast cancer. He is the national coordinating principal investigator of the PETREMAC (ClinicalTrials.gov Identifier: NCT02624973) and p53 breast trials (ClinicalTrials.gov Identifier: NCT02965950), where patients with breast cancer are given personalized cancer therapy, based on the molecular subtype of the tumor. He is heading the Bergen Breast Cancer Group and the K.G. Jebsen Center for genome-directed therapy in cancer (https://stiftkgj.no/what-we-do/k-g-jebsen-centres-of-medical-research/k-g-jebsen-center-for-genom-directed-therapy-in-cancer/?lang=en), together with Professor Per Eystein Lønning and Professor Stian Knappskog. 

HPE completed his PhD degree in 2002, with Professor Olav Dahl as main supervisor. He worked as a postdoctoral fellow at Harvard University, USA, 2007-09 in Professor Raghu Kalluri´s Division of Matrix Biology, and has an ongoing collaboration with Professor Kalluri at his current work site at MD Anderson Cancer Center in Houston, Texas. HPE joined the Bergen Breast Cancer Group in 2009, as a senior researcher. He has been employed as Professor in a 20% position at Dept. of Clinical Science, Faculty of Medicine, University of Bergen, from January 2019.

  • Show author(s) (2016). MEDIKAMENTELL KREFTBEHANDLING - CYTOSTATIKABOKEN Kapittel 19 - Hormoner og antihormoner . Universitetet i Oslo, Det medisinske fakultet, Institutt for klinisk medisin, Avdeling for farmakologi.
Academic article
  • Show author(s) (2022). PARP-inhibition reprograms macrophages toward an anti-tumor phenotype. Cell reports. 1-23.
  • Show author(s) (2022). Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clinical Cancer Research. 4714-4723.
  • Show author(s) (2022). DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. Breast Cancer Research. 1-14.
  • Show author(s) (2022). Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer. JAMA Oncology. 1579-1587.
  • Show author(s) (2022). Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. Genome Medicine. 1-18.
  • Show author(s) (2020). Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology. 1-10.
  • Show author(s) (2020). An ultrasensitive routine LC-MS/MS method for estradiol and estrone in the clinically relevant sub-picomolar range. Journal of the Endocrine Society (JES). 1-15.
  • Show author(s) (2019). Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI. Magnetic Resonance Materials in Physics, Biology and Medicine. 317-323.
  • Show author(s) (2019). Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Acta Oncologica. 385-387.
  • Show author(s) (2018). Divergent activity of the pseudogene PTENP1 in ER-positive and negative breast cancer. Molecular Cancer Research. 78-89.
  • Show author(s) (2018). BMP7 Signaling in TGFBR2-Deficient Stromal Cells Provokes Epithelial Carcinogenesis. Molecular Cancer Research. 1568-1578.
  • Show author(s) (2017). High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Research and Treatment. 177-190.
  • Show author(s) (2017). Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. OncoTarget. 41227-41241.
  • Show author(s) (2016). Lymphatic vessels regulate immune microenvironments in human and murine melanoma. Journal of Clinical Investigation. 3389-3402.
  • Show author(s) (2016). Impaired lymphatic function accelerates cancer growth. OncoTarget. 45789-45802.
  • Show author(s) (2016). Heterogenous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight. e90733.
  • Show author(s) (2016). BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European Journal of Human Genetics. 881-888.
  • Show author(s) (2014). TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta Oncologica. 1347-1355.
  • Show author(s) (2012). Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLOS ONE. 8 pages.
  • Show author(s) (2008). Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor therapy. Proceedings of the National Academy of Sciences of the United States of America. 15040-15045.
  • Show author(s) (2008). A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. The FASEB Journal. 3120-3128.
  • Show author(s) (1996). In vitro toksikologi på proximale tubuli celler. .
Academic lecture
  • Show author(s) (1996). Renal Cellular Changes Following X-Ray Contrast Media Exposure.
Reader opinion piece
  • Show author(s) (2013). Lethal pneumonitis after docetaxel chemotherapy: Case report and review of the literature. Acta Oncologica. 1034-1040.
Short communication
  • Show author(s) (2014). Tannhelse ved bruk av bisfosfonater mot brystkreft. Tidsskrift for Den norske legeforening. 1451-1451.
Doctoral dissertation
  • Show author(s) (2018). The role of PTEN, PI3K-Akt-mTOR signaling and pseudogene PTENP1 in breast cancer.
  • Show author(s) (2017). Role of the microenvironment and lymphatics in cancer development.
Academic chapter/article/Conference paper
  • Show author(s) (2011). The multifaceted role of cancer associated fibroblasts in tumor progression. 20 pages.
  • Show author(s) (2008). Complete separation and phenotyping of the tumor-host cellular compartments in tumor bearing nod/scid mice. Neuro-Oncology. 1148-1148.
  • Show author(s) (2019). Neoadjuvant olaparib monotherapy in primary triple negative breast cancer.
  • Show author(s) (2019). Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer.
  • Show author(s) (2020). Correction to: Semi-automatic segmentation from intrinsically-registered 18F-FDG–PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE–MRI (Magnetic Resonance Materials in Physics, Biology and Medicine, (2020), 33, 2, (317-328), 10.1007/s10334-019-00778-8). Magnetic Resonance Materials in Physics, Biology and Medicine. 329-330.
  • Show author(s) (2019). Correction to: Semi-automatic segmentation from intrinsically-registered 18F-FDG?PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE?MRI (Magnetic Resonance Materials in Physics, Biology and Medicine, (2019), 10.1007/s10334-019-00778-8). Magnetic Resonance Materials in Physics, Biology and Medicine.
Academic literature review
  • Show author(s) (2019). Constitutional mosaic epimutations - A hidden cause of cancer? Cell stress. 118-135.
  • Show author(s) (2014). The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy. 681-700.
  • Show author(s) (2013). Tumor vasculature: the Achilles' heel of cancer? Expert opinion on therapeutic targets. 7-20.
  • Show author(s) (2013). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer. R183-R201.
  • Show author(s) (2009). Drug resistance associated with antiangiogenesis therapy. Seminars in Cancer Biology. 310-317.
Article in business/trade/industry journal
  • Show author(s) (2014). Tannproblemer og adjuvant bisfosfonatbehandling hos pasienter med brystkreft. Den norske tannlegeforenings tidende. 571.
  • Show author(s) (2016). Kapittel 7 - Metabolske forstyrrelser ved kreft. 661 pages. In:
    • Show author(s) (2016). Medikamentell kreftbehandling - Cytostatikaboken 8. utgave 2016. Avdeling for farmakologi, Universitetet i Oslo.
  • Show author(s) (2016). Kapittel 14 - Tubulinhemmere. 661 pages. In:
    • Show author(s) (2016). Medikamentell kreftbehandling - Cytostatikaboken 8. utgave 2016. Avdeling for farmakologi, Universitetet i Oslo.

More information in national current research information system (CRIStin)